A Phase 4 interventional study of Artesunate + Amodiaquine in Malaria, sponsored by Sanofi. Completed at 1 site in Côte D'Ivoire. Per ClinicalTrials.gov, last updated 2015-02-23.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies testing artesunate in Malaria — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria.
Among the 68 studies testing artesunate in Malaria, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2009, is one of 27 in phase 4, and was the 37th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →None of the 68 studies testing artesunate in Malaria is open now. The open studies under Malaria, anywhere →
Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 19 · Phase 4 27
First in 2000; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 580 is above the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 290 across the 66 interventional studies. Of the 60 that completed or were terminated, 3 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 68 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
11 studies in Malaria by Sanofi: none open now, none under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 11 studies in Malaria by Sanofi, this one is the 3rd largest by enrollment, is the only one that started in 2009, is one of 5 in phase 4, and was the 9th registered.
Sanofi’s Malaria studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 68 studies testing artesunate in Malaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 11 in Malaria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to demonstrate the non-inferiority of Polymerase Chain Reaction (PCR)-adjusted adequate clinical and parasitological response to artesunate plus amodiaquine at Day 28 in two groups of patients treated at the beginning of an artesunate plus amodiaquine implementation program and 24 months later.
The secondary objectives are Clinical and biological tolerability Evolution of gametocyte carriage Proportion of patients without fever at Day 3 Proportion of patients without parasite at Day 3 Treatment compliance Impact of implementation on anemia Measure of parasite sensibility to amodiaquine
Inclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Oral fixed combination of artesunate (AS) and amodiaquine (AQ) Once daily, dose according to age Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister) Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister) Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister) Adults: \>= 14 years: AS 100/AQ 270 mg (6 tablets/ blister) 3 day-treatment
Drug: Artesunate + Amodiaquine
Drug pages: Artesunate · Amodiaquine
Artesunate + Amodiaquine fixed dose combination
Polymerase chain reaction (PCR)-corrected and uncorrected clinical and parasitological cure rate (ACPR)
Time frame: Day 28
Number of patients without fever
Time frame: Day 3
Number of patients without parasite
Time frame: Day 3
Number of gametocytes
Time frame: Day 3, Day 7, Day 14, Day 21 and Day 28
Evolution of in vitro resistance rate
Time frame: Day 3, Day 7, Day 14, Day 21 and Day 28
The record gives a start of Nov 2009, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Artesunate · Amodiaquine